Status:
COMPLETED
Chlorhexidine Gel Versus Alvogyl Following Surgical Extraction of Impacted Mandibular Third Molar
Lead Sponsor:
University of Baghdad
Conditions:
Impacted Third Molar Tooth
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Background: One of the most frequent surgical operations in dentistry is the surgical extraction of the impacted mandibular third molar, which is accompanied by a sequelae of swelling, trismus, and pa...
Detailed Description
Background: One of the most frequent surgical operations in dentistry is the surgical extraction of the impacted mandibular third molar, which is accompanied by a sequelae of swelling, trismus, and pa...
Eligibility Criteria
Inclusion
- Absence of any history of systemic diseases that can impede wound healing or surgical operation.
- No history of recently using anti-inflammatory drugs.
- Patients aged ≥18 years who were indicated for surgical extraction of mesioangular, class I or II, and position A or B impacted mandibular third molar.
- Well-educated patients who had no objection to take part in the study and likely to comply with all study procedures.
Exclusion
- Medical conditions that forbid surgical involvement, such as those in patients with bleeding-related conditions, recent myocardial infarctions, psychological issues, uncontrolled systemic diseases, immune-compromised patients, and patients who were on corticosteroid anti-inflammatory drugs.
- Recent history of head and neck radiotherapy.
- Pregnancy, and female patients taking contraceptives.
- Patients with severe localized infections in relation to the third molar, such as Pericoronitis, or those with severe periodontal disease and/or poor oral hygiene.
- Patients who were unable to come back for follow-up and recall appointments.
- Impacted third molar that interferes with the inferior alveolar nerve.
- Periapical pathology or cystic lesions related to the impacted tooth.
- Heavy smokers (more than 20 cigarettes/day).
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2022
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT06144983
Start Date
February 1 2022
End Date
September 1 2022
Last Update
November 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Baghdad
Baghdad, Iraq, 10064